Plain-English translation of NCT05299424 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new medication called CM336 for patients with multiple myeloma—a blood cancer—that has stopped responding to other treatments. The trial will first test different doses of the medication to find the safest and most effective level, then expand to treat more patients at that dose. Researchers want to understand how safe this treatment is and how well it works.
Many patients with advanced multiple myeloma run out of treatment options because their cancer becomes resistant to standard drugs. This medication is being developed to offer hope for people in that difficult situation by targeting the cancer in a new way.
You likely qualify if…
You likely don't qualify if…
Participants will receive injections of the medication at a clinic and be monitored closely for side effects and response to treatment. The first phase involves different patient groups receiving gradually higher doses to find the safest level, while the second phase expands treatment at the best-tolerated dose. You will have regular blood tests, imaging scans, and medical exams to track how you are responding and to watch for any problems.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
China